Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others) Some of the common fungal infections such as athlete's foot, fungal meningitis, ringworm and other infections can be treated by antifungal drugs that work by killing of the fungal cell breaking the contents of the cell. These cells eventually leak out and results in the death of the cell, which also prevents the cell to grow further, thus preventing the infection. The global antifungal drugs market was valued at $13,719 million in 2016, and is expected to reach at $17,718 million by 2023, registering a CAGR of 3.7% from 2017 to 2023.

There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.

The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global antifungal drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry, which helps understand the type of products and technologies used globally, is also included.
Key market players and their strategies are provided to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Drug Type

Echinocandins
Caspofungin
Micafungin
Anidulafungin
Others
Azoles
Imidazoles
Voriconazole
Thiazoles
Others
Polyenes
Amphotericin B
Candicidin
Hamycin
Natamycin
Others
Allylamines
Butenafine
Terbinafine
Naftifine
Others

By Infection Type

Superficial Antifungal Infections
Systemic Antifungal Infections

By Therapeutic Indications

Aspergillosis
Dermatophytosis
Candidiasis
Others

By Dosage Forms

Powders
Ointments
Drugs
Others

By Geography

North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Spain
Rest of Europe
Asia-pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Egypt
Israel
South Africa
Rest of LAMEA

KEY PLAYERS PROFILED

Pfizer Inc.
Sanofi S.A.
Gilead Sciences, Inc.
Merck & Co., Inc.
Scynexis Inc.
Novartis International AG
Abbott Laboratories
Bayer AG
Enzon Pharmaceuticals, Inc.
GlaxoSmithKline Plc.

The other players in the value chain include (profiles not included in the report)

Sigma-Aldrich Corporation
Agilent Technologies, Inc.
Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
Tecan Group
Astellas Pharma, Inc.
Basilea Pharmaceutical Ltd.
Valeant Pharmaceuticals International, Inc.
Kramer Laboratories